ID   BT-474 EEI
AC   CVCL_AR96
SY   BT474-EEI; BT474 EEI; BT-474 Exogenous Estrogen Independent
DR   cancercelllines; CVCL_AR96
DR   Wikidata; Q54798463
RX   PubMed=19010901;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0179 ! BT-474
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 05-10-23; Version: 12
//
RX   PubMed=19010901; DOI=10.1158/0008-5472.CAN-08-1776;
RA   Lewis Phillips G.D., Li G.-M., Dugger D.L., Crocker L.M., Parsons K.L.,
RA   Mai E., Blattler W.A., Lambert J.M., Chari R.V.J., Lutz R.J.,
RA   Wong W.L.T., Jacobson F.S., Koeppen H., Schwall R.H., Kenkare-Mitra S.R.,
RA   Spencer S.D., Sliwkowski M.X.;
RT   "Targeting HER2-positive breast cancer with trastuzumab-DM1, an
RT   antibody-cytotoxic drug conjugate.";
RL   Cancer Res. 68:9280-9290(2008).
//